Sionna Therapeutics (NASDAQ:SION) Shares Up 13.5% - What's Next?

Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report)'s stock price rose 13.5% on Wednesday . The company traded as high as $11.78 and last traded at $11.53. Approximately 73,565 shares were traded during trading, a decline of 68% from the average daily volume of 227,631 shares. The stock had previously closed at $10.16.

Wall Street Analyst Weigh In

Several brokerages recently commented on SION. Guggenheim started coverage on shares of Sionna Therapeutics in a research note on Tuesday, March 4th. They issued a "buy" rating and a $45.00 price objective for the company. Stifel Nicolaus began coverage on Sionna Therapeutics in a report on Tuesday, March 4th. They issued a "buy" rating and a $32.00 price target on the stock. Finally, TD Cowen began coverage on Sionna Therapeutics in a report on Tuesday, March 4th. They set a "buy" rating for the company.

Sionna Therapeutics Trading Down 2.4 %

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last released its quarterly earnings results on Thursday, March 20th. The company reported ($3.38) earnings per share for the quarter, missing analysts' consensus estimates of ($2.68) by ($0.70).

Sionna Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.